Literature DB >> 22655512

The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy.

Laura C McAdam1, Amanda L Mayo, Benjamin A Alman, W Douglas Biggar.   

Abstract

Deflazacort is the most commonly prescribed corticosteroid for the treatment of Duchenne muscular dystrophy in Canada. We review the long-term experience with deflazacort treatment at two centers in Canada; Montreal and Toronto. Deflazacort has benefitted both cohorts by prolonged ambulation, preserved cardiac and respiratory function, less scoliosis and improved survival. Common side effects in both cohorts include weight gain, decreased height and cataract formation. The Canadian experience supports the use of deflazacort in treating boys with Duchenne muscular dystrophy.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22655512      PMCID： PMC3440807     

Source DB:  PubMed          Journal:  Acta Myol        ISSN： 1128-2460


  30 in total

Review 1.  145th ENMC International Workshop: planning for an International Trial of Steroid Dosage Regimes in DMD (FOR DMD), 22-24th October 2006, Naarden, The Netherlands.

Authors:  K Bushby; R Griggs
Journal:  Neuromuscul Disord       Date:  2007-04-11       Impact factor: 4.296

2.  Duchenne muscular dystrophy: Canadian paediatric neuromuscular physicians survey.

Authors:  Hugh J McMillan; Craig Campbell; Jean K Mah
Journal:  Can J Neurol Sci       Date:  2010-03       Impact factor: 2.104

3.  Bone health in boys with Duchenne Muscular Dystrophy on long-term daily deflazacort therapy.

Authors:  A L Mayo; B C Craven; L C McAdam; W D Biggar
Journal:  Neuromuscul Disord       Date:  2012-07-21       Impact factor: 4.296

Review 4.  Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management.

Authors:  Richard T Moxley; Shree Pandya; Emma Ciafaloni; Deborah J Fox; Kim Campbell
Journal:  J Child Neurol       Date:  2010-06-25       Impact factor: 1.987

5.  Duchenne muscular dystrophy: a 30-year population-based incidence study.

Authors:  Joseph Dooley; Kevin E Gordon; Linda Dodds; Judith MacSween
Journal:  Clin Pediatr (Phila)       Date:  2010-02       Impact factor: 1.168

Review 6.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management.

Authors:  Katharine Bushby; Richard Finkel; David J Birnkrant; Laura E Case; Paula R Clemens; Linda Cripe; Ajay Kaul; Kathi Kinnett; Craig McDonald; Shree Pandya; James Poysky; Frederic Shapiro; Jean Tomezsko; Carolyn Constantin
Journal:  Lancet Neurol       Date:  2009-11-27       Impact factor: 44.182

Review 7.  Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care.

Authors:  Katharine Bushby; Richard Finkel; David J Birnkrant; Laura E Case; Paula R Clemens; Linda Cripe; Ajay Kaul; Kathi Kinnett; Craig McDonald; Shree Pandya; James Poysky; Frederic Shapiro; Jean Tomezsko; Carolyn Constantin
Journal:  Lancet Neurol       Date:  2009-11-27       Impact factor: 44.182

8.  Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up.

Authors:  Sylvie Houde; Michèle Filiatrault; Anne Fournier; Julie Dubé; Sylvie D'Arcy; Denis Bérubé; Yves Brousseau; Guy Lapierre; Michel Vanasse
Journal:  Pediatr Neurol       Date:  2008-03       Impact factor: 3.372

9.  Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade.

Authors:  W D Biggar; V A Harris; L Eliasoph; B Alman
Journal:  Neuromuscul Disord       Date:  2006-03-20       Impact factor: 4.296

Review 10.  Glucocorticoid corticosteroids for Duchenne muscular dystrophy.

Authors:  A Y Manzur; T Kuntzer; M Pike; A Swan
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23
View more
  19 in total

1.  Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study.

Authors:  Luca Bello; Heather Gordish-Dressman; Lauren P Morgenroth; Erik K Henricson; Tina Duong; Eric P Hoffman; Avital Cnaan; Craig M McDonald
Journal:  Neurology       Date:  2015-08-26       Impact factor: 9.910

2.  Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients.

Authors:  Yetrib Hathout; Ramya L Marathi; Sree Rayavarapu; Aiping Zhang; Kristy J Brown; Haeri Seol; Heather Gordish-Dressman; Sebahattin Cirak; Luca Bello; Kanneboyina Nagaraju; Terry Partridge; Eric P Hoffman; Shin'ichi Takeda; Jean K Mah; Erik Henricson; Craig McDonald
Journal:  Hum Mol Genet       Date:  2014-07-15       Impact factor: 6.150

Review 3.  Treatment of dystrophin cardiomyopathies.

Authors:  Josef Finsterer; Linda Cripe
Journal:  Nat Rev Cardiol       Date:  2014-01-14       Impact factor: 32.419

Review 4.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management.

Authors:  David J Birnkrant; Katharine Bushby; Carla M Bann; Susan D Apkon; Angela Blackwell; David Brumbaugh; Laura E Case; Paula R Clemens; Stasia Hadjiyannakis; Shree Pandya; Natalie Street; Jean Tomezsko; Kathryn R Wagner; Leanne M Ward; David R Weber
Journal:  Lancet Neurol       Date:  2018-02-03       Impact factor: 44.182

5.  SU9516 Increases α7β1 Integrin and Ameliorates Disease Progression in the mdx Mouse Model of Duchenne Muscular Dystrophy.

Authors:  Apurva Sarathy; Ryan D Wuebbles; Tatiana M Fontelonga; Ashley R Tarchione; Lesley A Mathews Griner; Dante J Heredia; Andreia M Nunes; Suzann Duan; Paul D Brewer; Tyler Van Ry; Grant W Hennig; Thomas W Gould; Andrés E Dulcey; Amy Wang; Xin Xu; Catherine Z Chen; Xin Hu; Wei Zheng; Noel Southall; Marc Ferrer; Juan Marugan; Dean J Burkin
Journal:  Mol Ther       Date:  2017-04-05       Impact factor: 11.454

6.  No difference in postoperative complication rates or cardiopulmonary function for early versus late scoliosis correction in Duchenne muscular dystrophy.

Authors:  Ali Asma; Armagan Can Ulusaloglu; Michael Wade Shrader; William G Mackenzie; Robert Heinle; Mena Scavina; Jason J Howard
Journal:  Spine Deform       Date:  2022-06-13

7.  A population-based study of scoliosis among males diagnosed with a dystrophinopathy identified by the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet).

Authors:  Kristin M Conway; Amber Gedlinske; Katherine D Mathews; Seth Perlman; Nicholas Johnson; Russell Butterfield; Man Hung; Jerry Bounsanga; Dennis Matthews; Joyce Oleszek; Paul A Romitti
Journal:  Muscle Nerve       Date:  2021-12-01       Impact factor: 3.852

8.  Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy.

Authors:  Molly M Lamb; Nancy A West; Lijing Ouyang; Michele Yang; David Weitzenkamp; Katherine James; Emma Ciafaloni; Shree Pandya; Carolyn DiGuiseppi
Journal:  J Pediatr       Date:  2016-03-30       Impact factor: 4.406

Review 9.  Current and Emerging Therapies for Duchenne Muscular Dystrophy.

Authors:  Megan Crone; Jean K Mah
Journal:  Curr Treat Options Neurol       Date:  2018-06-23       Impact factor: 3.598

10.  Genetic modifiers of ambulation in the Cooperative International Neuromuscular Research Group Duchenne Natural History Study.

Authors:  Luca Bello; Akanchha Kesari; Heather Gordish-Dressman; Avital Cnaan; Lauren P Morgenroth; Jaya Punetha; Tina Duong; Erik K Henricson; Elena Pegoraro; Craig M McDonald; Eric P Hoffman
Journal:  Ann Neurol       Date:  2015-03-13       Impact factor: 10.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.